Tirzepatide and semaglutide offer weight loss through weekly injections, however, as many scramble to obtain these medications, the supply chain has made this difficult. Semaglutide and tirzepatide have three main mechanisms of action. They enhance the growth of beta cells in the pancreas, which are sites of insulin production. This means your body has improved control over blood sugar or decreased insulin resistance. Compounded tirzepatide with B12 and semaglutide with BPC-157 or B12 markedly delay gastric emptying. The delay in gastric emptying can reduce appetite. Finally, both medications improve control of eating and reduce food cravings. The last mechanism is what many people appreciate the most, feeling less compulsion to eat or not eating as much.
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide–GLP-1 receptor agonist. This means this medication works on two different receptors, GIP and GLP-1. The GIP receptors are activated to improve insulin sensitivity, insulin secretion, satiety (feeling full), and fat burn (lipolysis). Simultaneously, the GLP-1 receptors are stimulated to decrease glucagon secretion, slow gastric emptying, and decrease appetite. Concurrent action on both GIP and GLP-1 produces weight loss, lowered cholesterol, and reduced cardiovascular risk for patients.
The dosing for compounded tirzepatide with B12 starts at 2.5mg per week and increases based on the patient’s response. Thus dose increases with tirzepatide with B12 are less frequent, once every 4-6 weeks on average. Semaglutide with BPC-157 or B12 dosing starts at 0.25mg per week and increases weekly, based on the patients’ response. Both medications aim not to achieve the maximum dose but to have controlled, monitored, and safe weight loss with minimal side effects.
| Indications/Contraindications | Semaglutide With BPC-157 or B12 | Tirzepatide With B12 |
| Overweight | Yes | Yes |
| Prediabetic or Diabetic | Yes | Yes |
| Oral Contraceptives | Yes | No |
| Pregnant, Breast Feeding, and or Trying to Conceive | No | No |
| Family History | Contraindicated with a family history of thyroid cancer or multiple endocrine neoplasia type II | Contraindicated with a family history of thyroid cancer or multiple endocrine neoplasia type II |
| Medical History | Contraindicated with pancreatitis history | Contraindicated with pancreatitis history |
The short answer is yes! Yes, you can. However, your insurance company may not approve this, and the cost may be out of pocket. The medicine may prevent you from becoming diabetic if you are currently pre-diabetic. An additional advantage of these medications is the long-term risk reduction of stroke and heart attack. Generally, everyone wants to “look good naked,” and dropping the extra 30+ pounds has lifelong benefits. This weight loss will often accompany lower cholesterol, reducing your risk of having a heart attack or stroke. Not carrying around an extra 30 pounds for the next 30-plus years will improve your joint health and mobility. Patients may be able to avoid or delay hip, knee, and or ankle replacement.
Compounding pharmacies make medications from scratch to tailor the dosage to the individual patient. These pharmacies are safe and regulated by the state Board of Pharmacy and have frequent inspections for sterile processing.
A unique advantage to compounding pharmacies is combining medications for increased efficacy and patient tolerance. Moblie Care Health offers semaglutide compounded with BPC-157, which increases semaglutide’s efficacy. Tirzepatide is compounded with B12, reducing nausea that frequently occurs with both medications.
Manufactured semaglutide and tirzepatide come in pen form with preset dosing amounts. The pen has a needle and a dial to turn for each dose. This means that the patient and the provider are stuck with the dosages the manufacturer has preset into the pen. Subsequently, compounded semaglutide with BPC-157 or B12 and tirzepatide with B12 dosages can also be tailored to the patient. The recommended dose for semaglutide starts at 0.25mg/week, but some patients may do better on lower or higher doses depending on their individual response and tolerability. Tirzepatide starts at 2.5mg/week and increases every 4-6 weeks as the patient tolerates it. Pens force patients to double their dose instead of a gradual increase. Compounded semaglutide with BPC-157 or B12 and tirzepatide with B12 in a vial offer the flexibility of gradually increasing a patient’s dose. This means we can work with patients to increase their dose in relation to side effects all while reaching their weight loss goal.
CJC-1295 stimulates HGH secretion and can provide a steady increase of HGH (Human Growth Hormone) with minimal effect on cortisol and prolactin levels. This means increased protein synthesis, promotion of growth, and fat loss simultaneously. Ipamorelin mimics ghrelin and binds to the brain’s ghrelin receptor (or GH secretagogue receptor, GHSR). Thus patients have decreased body fat percentage, making it synergistic when combined with semaglutide or tirzepatide. Tesamorelin offers similar benefits with more focus on abdominal fat loss. This combination is an excellent aid for sleep, energy, stamina, and recovery benefits.
Ready to get started on compounded tirzepatide or compounded semaglutide? Book a consult today with Mobile Care Health. Obesity is a national epidemic. “Finally, we have two medications that are proven effective in this battle,” relates Dr. Jacob Weinstein DNP, with Mobile Care Health. He added, “Obesity is often not treated in primary care because physicians and nurse practitioners are not reimbursed for preventative care. Now we have great patient options and a supply issue, thankfully, compounded tirzepatide with B12 and compounded semaglutide with BPC-157 or B12 are available.” Mobile Care Health provides FAQ’s for semaglutide and tirzepatide.
Copyright © 2024, Mobile Care | All Rights Reserved | Patient Portal | Refund Policy | Privacy Policy